DocWire News Editors

DocwireNews

<h2 class="entry-title"><a href="https://www.docwirenews.com/docwire-pick/second-line-liposomal-irinotecan-in-small-cell-lung-cancer/">RESILIENT Trial: Second-Line Liposomal Irinotecan in Small Cell Lung Cancer</a><p>The first phase of the RESILIENT trial was comprised of dose-exploration and dose-expansion in a total cohort of 25 patients with SCLC. The primary goal of the trial were to define the safety and tolerability profiles, and to identify a recommended dose. Primary efficacy endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).</p><h2><a href="https://www.docwirenews.com/docwire-pick/immune-checkpoint-inhibitors-relapsed-small-cell-lung-cancer/">Immune Checkpoint Inhibitors in Relapsed Small Cell Lung Cancer</a></h2><p>Immune checkpoint inhibitors (ICIs) are approved for treatment of small cell lung cancer (SCLC). However, according to Yulian Xu and colleagues, the efficacy and safety of ICIs in relapsed SCLC are unclear. They performed a systematic review of published ICI studies and reported that &ldquo;the administration of ICIs resulted in a similar survival outcome and acceptable safety compared with chemotherapy&rdquo; for patients with relapsed SCLC.</p><h2 class="entry-title"><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/circular-rna-ataxin-7-in-non-small-cell-lung-cancer/">Circular RNA Ataxin 7 in Non-Small Cell Lung Cancer</a></h2><p>According to a report in&nbsp;<em>Thoracic Cancer</em>, circular RNA ataxin 7 (circATXN7) has been shown to have a &ldquo;promoting influence&rdquo; on disease progression in patients with gastric cancers, but its role in non-small cell lung cancer (NSCLC) is unclear. Researchers examined levels of the circular RNA, Ataxin 7 and observed that correlated withthe malignancy of NSCLC cells.</p><h2><a href="https://www.docwirenews.com/docwire-pick/outcomes-of-anlotinib-in-patients-with-small-cell-lung-cancer-and-liver-metastasis/">Outcomes of Anlotinib in Patients with Small Cell Lung Cancer and Liver Metastasis</a></h2><p>Researchers set out to characterize survival outcomes in patients with small cell lung cancer (SCLC) treated with anlotinib in the ALTER 1202 trial, including those with liver metastasis. After their post hoc analysis, the study&rsquo;s primary investigator, Ying Cheng, and colleagues reported that anlotinib appeared to improve progression-free survival (PFS) in patients with SCLC compared to a placebo.</p><h2 class="entry-title"><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/examining-small-cell-breast-carcinoma-treatment-and-prognosis/">Examining Small Cell Breast Carcinoma Treatment and Prognosis</a></h2><p>In a randomized controlled trial, published in&nbsp;<em>Frontiers in Endocrinology</em>, researchers aimed to further characterize the incidence, clinical pathology, and potential prognostic factors of primary small cell breast carcinoma (SCBC). Primary investigator, Jiahao Zhu, and colleagues reported that SCBC is a &ldquo;rare, aggressive tumor that needs uniform multimodality therapies,&rdquo; and they proposed that combined surgery and chemotherapy is the optimal approach in small cell breast carcinoma treatment.</p></h2>


Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Oncology Round-Up: Immune Checkpoint Inhibitors; and More

Oncology

RESILIENT Trial: Second-Line Liposomal Irinotecan in Small Cell Lung Cancer ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe